4-(4-hydroxy-2-oxo-3-propionyl-2H-pyran-6-yl)butanal | 808132-42-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(4-hydroxy-2-oxo-3-propionyl-2H-pyran-6-yl)butanal
• 英文别名: 4-(4-Hydroxy-2-oxo-3-propionyl-2H-pyran-6-yl)butanal；4-(4-hydroxy-6-oxo-5-propanoylpyran-2-yl)butanal
• CAS: 808132-42-5
• 化学式: C₁₂H₁₄O₅
• 分子量: 238.24
• InChiKey: YESJXQWYDVUTQV-UHFFFAOYSA-N

物化性质

• 沸点：
  414.8±45.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(4-hydroxy-2-oxo-3-propionyl-2H-pyran-6-yl)butanal 在 lithium hydroxide 、 四氯化钛 、 sodium hydride 、 甲基磺酰氯 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 72.75h， 生成
  参考文献：
  名称：

  Myxopyronin B analogs as inhibitors of RNA polymerase, synthesis and biological evaluation

  摘要：

  A series of myxopyronin B analogs has been prepared via a convergent synthetic route and were tested for in vitro inhibitory activity against DNA-dependent RNA polymerase and antibacterial activity against E. coli and S. aureus. The parent lead compound proved to be very sensitive to even small changes. Only the achiral desmethyl myxopyronin B (1a) provided enhanced potency. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.045
• 作为产物：
  描述：

  6-(4-((t-butyldimethylsilyl)oxy)butyl)-4-hydroxy-3-propionyl-2H-pyran-2-one 在 溶剂黄146 作用下， 以 四氢呋喃 、 吡啶 、 二氯甲烷 、 水 为溶剂， 反应 21.0h， 生成 4-(4-hydroxy-2-oxo-3-propionyl-2H-pyran-6-yl)butanal
  参考文献：
  名称：

  Antibacterial agents: high-potency myxopyronin derivatives

  摘要：

  该发明提供了化合物的公式(I)及其药用盐，其中Ya、Yb、R1、R2和G如规范中所述，以及包含公式(I)化合物的组合物。这些化合物可用作细菌RNA聚合酶的抑制剂和抗菌剂。

  公开号：

  US09133155B2

文献信息

• Antibacterial agents: high-potency myxopyronin derivatives
  申请人：Ebright Richard H.

  公开号：US09133155B2

  公开（公告）日：2015-09-15

  The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Ya, Yb, R1, R2, and G are as described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as inhibitors of bacterial RNA polymerase and as antibacterial agents.

  该发明提供了化合物的公式(I)及其药用盐，其中Ya、Yb、R1、R2和G如规范中所述，以及包含公式(I)化合物的组合物。这些化合物可用作细菌RNA聚合酶的抑制剂和抗菌剂。
• ANTIBACTERIAL AGENTS: HIGH-POTENCY MYXOPYRONIN DERIVATIVES
  申请人：Ebright Richard H.

  公开号：US20130237595A1

  公开（公告）日：2013-09-12

  The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Ya, Yb, R1, R2, and G are as described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as inhibitors of bacterial RNA polymerase and as antibacterial agents.

  本发明提供了公式（I）的化合物及其药学上可接受的盐，其中Ya、Yb、R1、R2和G如规范所述，以及包含公式（I）化合物的组合物。这些化合物可用作细菌RNA聚合酶的抑制剂和抗菌剂。
• US9133155B2
  申请人：——

  公开号：US9133155B2

  公开（公告）日：2015-09-15
• [EN] ANTIBACTERIAL AGENTS: HIGH-POTENCY MYXOPYRONIN DERIVATIVES<br/>[FR] AGENTS ANTIBACTÉRIENS : DÉRIVÉS DE MYXOPYRONINE DE PUISSANCE ÉLEVÉE
  申请人：UNIV RUTGERS

  公开号：WO2012037508A2

  公开（公告）日：2012-03-22

  The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Ya, Yb, R1, R2, and G are as described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as inhibitors of bacterial RNA polymerase and as antibacterial agents.
• Novel Hybrid-Type Antimicrobial Agents Targeting the Switch Region of Bacterial RNA Polymerase
  作者：Fumika Yakushiji、Yuko Miyamoto、Yuki Kunoh、Reiko Okamoto、Hidemasa Nakaminami、Yuri Yamazaki、Norihisa Noguchi、Yoshio Hayashi

  DOI：10.1021/ml300350p

  日期：2013.2.14

  The bacterial RNA polymerase (RNAP) is an ideal target for the development of antimicrobial agents against drug-resistant bacteria. Especially, the switch region within RNAP has been considered as an attractive binding site for drug discovery. Here, we designed and synthesized a series of novel hybrid-type inhibitors of bacterial RNAP. The antimicrobial activities were evaluated using a paper disk diffusion assay, and selected derivatives were tested to determine their MIC values. The hybrid-type antimicrobial agent 29 showed inhibitory activity against Escherichia coli RNAP. The molecular docking study suggested that the RNAP switch region would be the binding site of 29.